Discover the elements of efficacy and safety with TREANDA

TREANDA is a uniquely designed single-agent therapy that is indicated for chronic lymphocytic leukemia (CLL). In the pivotal phase 3 trial, TREANDA demonstrated improved efficacy vs chlorambucil, tripling median progression-free survival (PFS) (18 months [95% CI: 11.7, 23.5] vs 6 months [95% CI: 5.6, 8.6]) and doubling the overall response rates (ORR) (59% [95% CI: 51.03, 66.62] vs 26% [95% CI: 18.64, 32.71]).¹

TREANDA was also generally well tolerated in the clinical trial. Patients were adherent to the dosing schedule and most patients did not receive granulocyte growth factor support (use of growth factors was discouraged according to protocol) or experience alopecia.^1,2

The most common non-hematologic adverse reactions (frequency ≥15%) were pyrexia (24%), nausea (20%), and vomiting (16%) (n=153). The most common hematologic abnormalities (frequency ≥15%) were anemia (89%), thrombocytopenia (77%), neutropenia (75%), lymphopenia (68%), and leukopenia (61%) (n=150).

Additionally, TREANDA is a uniquely designed agent that may cause dual cell death via multiple pathways.^3-6 The exact mechanism of TREANDA is unknown. Adverse reactions may require interventions such as decreasing the dose of TREANDA or withholding or delaying treatment.

Please explore the site to learn more about the clinical efficacy of prescribing TREANDA for your patients with CLL. You’ll also find helpful educational resources and reimbursement assistance and support that may benefit you and your patients.

Indications

TREANDA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.

TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Important Safety Information

• Serious adverse reactions, including myelosuppression, infections, infusion reactions and anaphylaxis, tumor lysis syndrome, skin reactions including SJS/TEN, other malignancies, and extravasation, have been associated with TREANDA. Some reactions, such as myelosuppression, infections, and SJS/TEN (when TREANDA was administered concomitantly with allopurinol and other medications known to cause SJS/TEN), have been fatal. Patients should be monitored closely for these reactions and treated promptly if any occur
  
  
• Adverse reactions may require interventions such as decreasing the dose of TREANDA, or withholding or delaying treatment
  
  
• TREANDA is contraindicated in patients with a known hypersensitivity to bendamustine or mannitol. Women should be advised to avoid becoming pregnant while using TREANDA
  
  
• The most common non-hematologic adverse reactions associated with TREANDA (frequency ≥15%) were pyrexia, nausea, and vomiting. The most common hematologic abnormalities associated with TREANDA (frequency ≥15%) were anemia, thrombocytopenia, neutropenia, lymphopenia, and leukopenia

TO REPORT SIDE EFFECTS: Contact us at 1-800-896-5855 or usmedinfo@cephalon.com